Sign In to Request a Protocol
Sign In to Request a Protocol

Cagrilintide (10 mg Vial) Dosage Protocol

  • Table of Contents

Cagrilintide Dosage Chart

Cagrilintide is dosed at 600 mcg–4.5 mg weekly by subcutaneous injection in educational protocols, starting low and titrating upward. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
  • Typical weekly range: 0.6–4.5 mg once weekly (gradual titration over 4–6 weeks).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 0.0333 mg (33.3 mcg) on a U-100 insulin syringe.
  • Storage: Lyophilized: store frozen at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days.

Cagrilintide is a long‑acting acylated analogue of the pancreatic hormone amylin, designed for once‑weekly subcutaneous administration. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake. In phase 2 and phase 3 trials, cagrilintide produced dose‑dependent weight loss with a predominantly gastrointestinal side‑effect profile.

  • Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Route: Subcutaneous injection. Frequency: Once weekly on a consistent day.
PhaseDaily Dose (mg)Units (per injection) (mL)Volume (mL)
Weeks 1–20.6 mg18 units0.18 mL
Weeks 3–41.2 mg36 units0.36 mL
Weeks 5–62.4 mg72 units0.72 mL
Weeks 7–16 (Maintenance)4.5 mg135 units1.35 mL

Note: The maintenance dose of 4.5 mg requires 135 units (1.35 mL), which exceeds a standard U‑100 insulin syringe capacity. Use a 3 mL syringe with an appropriate subcutaneous needle (e.g., 25–27G, ½–⅝ inch) for doses above 1.0 mL. For titration doses (≤72 units), a U‑100 insulin syringe provides excellent accuracy.

Reconstitution Steps

  • 1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2. Inject slowly down the vial wall; avoid foaming or vigorous agitation.
  • 3. Gently swirl or roll until fully dissolved (do not shake).
  • 4. Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  • 5. Use within 30 days of reconstitution; discard if cloudy or particulate matter appears.
Important: This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
  • Supplies Needed
Plan based on an 8–16 week weekly protocol with gradual titration.
  • Peptide Vials (Cagrilintide, 10 mg each):
  • 8 weeks ≈ 2 vials (17.4 mg total needed)
  • 12 weeks ≈ 4 vials (35.4 mg total needed)
  • 16 weeks ≈ 6 vials (53.4 mg total needed)
  • Syringes:
  • Weeks 1–6 (doses ≤72 units): U-100 insulin syringes work well
  • Weeks 7+ (doses >100 units): 3 mL syringes with 25–27G subcutaneous needles
  • Per week: 1 syringe
  • 8 weeks: 8 syringes
  • 12 weeks: 12 syringes
  • 16 weeks: 16 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
  • 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each week.
  • Per week: 2 swabs
  • 8 weeks: 16 swabs
  • 12 weeks: 24 swabs
  • 16 weeks: 32 swabs → recommend 1 × 100-count box
  • Protocol Overview
Concise summary of the once‑weekly regimen.
  • Goal: Support satiety, reduce food intake, and promote weight management over time.
  • Schedule: Weekly subcutaneous injections for 12–16 weeks (or longer as appropriate).
  • Dose Range: 0.6–4.5 mg weekly with gradual titration every 2 weeks.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for practical volume measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw cycles.
  • Dosing Protocol
Suggested weekly titration approach based on clinical trial designs.
  • Start: 0.6 mg weekly for the first 2 weeks to assess tolerability.
  • Escalate: Double the dose every 2 weeks (0.6 → 1.2 → 2.4 → 4.5 mg) as tolerated.
  • Target: 4.5 mg weekly by Weeks 7–8; maintain at this dose.
  • Frequency: Once per week (subcutaneous) on the same day each week.
  • Timing: Any consistent time; rotate injection sites.
  • Storage Instructions
Proper storage preserves peptide integrity and potency.
  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw cycles.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Important Notes
Practical considerations for consistency and tolerability.
  • Use new sterile syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation.
  • Gradual dose escalation minimizes gastrointestinal side effects such as nausea.
  • Document weekly dose, injection site, and any adverse effects to maintain consistency.
  • For maintenance doses requiring >1.0 mL, ensure you have appropriately sized syringes (3 mL).
  • How This Works

Cagrilintide is an acylated, long‑acting analogue of amylin—a hormone co‑secreted with insulin from pancreatic beta cells. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake. Lipid modifications extend its half‑life to approximately 160–195 hours, enabling once‑weekly dosing.

  • Potential Benefits & Side Effects
Observations from phase 2 and phase 3 clinical trials.
  • Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo.
  • Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone.
  • Dose-dependent efficacy: Higher doses (2.4–4.5 mg) demonstrate greater weight loss than lower doses (0.3–1.2 mg).
  • Side effects: Primarily gastrointestinal—nausea, vomiting, diarrhea, and constipation—which are generally mild-to-moderate and transient. Gradual titration helps minimize these effects.
  • Injection-site reactions: Occasional mild redness or irritation at subcutaneous injection sites.
  • Lifestyle Factors
Complementary strategies for optimal outcomes.
  • Pair with a balanced, protein‑forward diet tailored to individual energy needs.
  • Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
  • Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery.
  • Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.
  • Injection Technique
General subcutaneous guidance from clinical best‑practice resources.
  • Clean the vial stopper and skin with alcohol; allow to air dry completely.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
  • Do not aspirate for subcutaneous injections; inject slowly and steadily.
  • Hold for 5–10 seconds before withdrawing the needle to ensure complete delivery.
  • Rotate sites systematically (abdomen, thighs, upper arms) each week to avoid lipohypertrophy.
  • Recommended Source
We recommend Vitality Labs Peptides for high-purity 5-Amino-1MQ (50 mg).

Why Vitality Labs Peptides?

  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.
Contact on Telegram
  • Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
  • References

Explore related research dosage protocols and background reading for BPC-157 + TB-500.

The Lancet (2021)

— Once‑weekly cagrilintide for weight management: phase 2 dose‑finding trial (Lau et al.)
More Info

Int J Mol Sci (2024)

— Amylin, another important neuroendocrine hormone for treatment of diabesity
More Info

PMC (2022)

— Mediators of amylin action in metabolic control
More Info

The Lancet (2021)

— Cagrilintide phase 2 trial: 10.8% weight loss at 4.5 mg dose over 26 weeks
More Info

N Engl J Med (2025)

— REDEFINE 1: Coadministered cagrilintide and semaglutide in adults with overweight or obesity
More Info

The Lancet (2021)

— Cagrilintide + semaglutide phase 1b trial: safety, tolerability, pharmacokinetics (Enebo et al.)
More Info

J Med Chem (2021)

— Development of cagrilintide: a long‑acting amylin analogue View Source
More Info

Brain Res Rev (2005)

— Pancreatic amylin as a centrally acting satiating hormone
More Info

PMC (2006)

— Pancreatic signals controlling food intake: insulin, glucagon, and amylin
More Info

PMC (2016)

— Amylin‑mediated control of glycemia, energy balance, and cognition
More Info

PMC (2024)

— Clinical pharmacokinetics of semaglutide: systematic review (includes cagrilintide PK data)
More Info

N Engl J Med (2025)

— REDEFINE 2: Cagrilintide–semaglutide in adults with overweight/obesity and type 2 diabetes
More Info

CDC

— Vaccine administration: subcutaneous injection technique and site guidance
More Info

CDC (PDF)

— You Call the Shots: subcutaneous injection diagram and best practices
More Info

PMC (2019)

— Subcutaneous drug delivery: pharmacologic considerations and techniques
More Info

American College of Cardiology (2025)

— REDEFINE 1 and REDEFINE 2 journal scan summary
More Info

The Lancet (2023)

— Efficacy and safety of CagriSema in type 2 diabetes: phase 2 trial (Frias et al.)
More Info

PMC (2024)

— Efficacy and safety of cagrilintide and CagriSema: systematic review and meta‑analysis
More Info

Vitality Lab Peptides

— Cagrilintide (10 mg) product page (quality and batch documentation)
More Info